Media stories about argenx (NASDAQ:ARGX) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. argenx earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news articles about the company an impact score of 46.3033150457103 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- 3 Things In Biotech, June 21: Regeneron Sneaks Up In The Kidney Cancer Space (seekingalpha.com)
- argenx (ARGX) Reports Interim Data from First Cohort of Phase 2 proof-of-concept Clinical Trial of Efgartigimod for Treatment of PV (streetinsider.com)
- SunTrust Banks Comments on argenx SE -‘s Q2 2018 Earnings (ARGX) (americanbankingnews.com)
- Brokerages Anticipate argenx SE – (ARGX) Will Announce Quarterly Sales of $12.17 Million (americanbankingnews.com)
- -$0.43 Earnings Per Share Expected for argenx SE – (ARGX) This Quarter (americanbankingnews.com)
ARGX has been the subject of several recent research reports. Cowen reiterated a “buy” rating on shares of argenx in a research report on Wednesday, June 6th. Wedbush reiterated an “outperform” rating and issued a $92.00 price target (down from $93.00) on shares of argenx in a research report on Thursday, May 10th. Piper Jaffray Companies restated an “overweight” rating and set a $130.00 target price on shares of argenx in a research report on Thursday, June 7th. Zacks Investment Research cut argenx from a “hold” rating to a “sell” rating in a research report on Wednesday, March 7th. Finally, JMP Securities boosted their target price on argenx from $93.00 to $130.00 and gave the stock a “positive” rating in a research report on Monday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. argenx currently has an average rating of “Buy” and a consensus price target of $110.80.
argenx Company Profile
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.